| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Merieux Institute |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002069 |
Purpose
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.
| Condition | Intervention |
|
HIV Infections |
Drug: Ditiocarb sodium |
| MedlinePlus related topics: | AIDS |
| Drug Information available for: | Ditiocarb sodium |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Study of DTC in Patients With AIDS and AIDS Related Complex |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded within 3 weeks of study entry:
Patients with the following are excluded:
Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.
Contacts and Locations| United States, Arizona | |||||
| Univ of Arizona / Arizona Cancer Ctr | |||||
| Tucson, Arizona, United States, 85724 | |||||
| United States, California | |||||
| San Francisco AIDS Clinic / San Francisco Gen Hosp | |||||
| San Francisco, California, United States, 941102859 | |||||
| Portion Med Group | |||||
| Sherman Oaks, California, United States, 91403 | |||||
| USC School of Medicine / Norris Cancer Hosp | |||||
| Los Angeles, California, United States, 90033 | |||||
| United States, Florida | |||||
| Florida Keys Memorial Hosp | |||||
| Key West, Florida, United States, 33040 | |||||
| United States, New York | |||||
| SUNY / Health Sciences Ctr at Brooklyn | |||||
| Brooklyn, New York, United States, 11203 | |||||
| United States, North Carolina | |||||
| Duke Univ Med Ctr | |||||
| Durham, North Carolina, United States, 27710 | |||||
| United States, Texas | |||||
| Dr Gary Brewton | |||||
| Houston, Texas, United States, 77027 | |||||
| Merieux Institute |
More Information
|
Hersh EM, et al. A randomized, double-blind, placebo-controlled trial of diethyldithiocarbamate (Ditiocarb, Imuthiol(R) in patients with ARC and AIDS. Int Conf AIDS. 1990 Jun 20-23;6(3):208 (abstract no SB489)
|
| Study ID Numbers: | 010A |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002069 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
